Effective asparagine depletion with pegylated asparaginase results in improved outcomes in adult acute lymphoblastic leukemia: Cancer and Leukemia Group B study 9511

Blood

Volumn 109, Issue 10, 2007, Pages 4164-4167

  Wetzler, Meir ^a   Sanford, Ben L ^b   Kurtzberg, Joanne ^b   DeOliveira, Divino ^b   Frankel, Stanley R ^c   Powell, Bayard L ^d   Kolitz, Jonathan E ^e   Bloomfield, Clara D ^f   Larson, Richard A ^g  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c UNIVERSITY OF MARYLAND GREENEBAUM CANCER CENTER   (United States)

^d WAKE FOREST SCHOOL OF MEDICINE   (United States)

^e NORTH SHORE UNIVERSITY HOSPITAL   (United States)

^f OHIO STATE UNIVERSITY   (United States)

^g UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARAGINASE MACROGOL; ASPARAGINE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER SURVIVAL; CLINICAL STUDY; CONTROLLED STUDY; ENZYME BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN DEPLETION; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 34248325307     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2006-09-045351     Document Type: Article

References (20)

1. Broome JD. Evidence that the L-asparaginase of guinea pig serum is responsible for its antilymphoma effects. Nature. 1961;191:1114-1115.
2. Keating MJ, Holmes R, Lerner S, Ho DH. L-asparaginase and PEG asparaginase - past, present, and future. Leuk Lymphoma. 1993;10(suppl):153-157.
3. Asselin BL, Whitin JC, Coppola DJ, Rupp IP, Sallan SE, Cohen HJ. Comparative pharmacokinetic studies of three asparaginase preparations. J Clin Oncol. 1993;11:1780-1786.
4. Asselin BL, Ryan D, Frantz CN, et al. In vitro and in vivo killing of acute lymphoblastic leukemia cells by L-asparaginase. Cancer Res. 1989;49:4363-4368.
5. Ettinger LJ, Kurtzberg J, Voute PA, Jurgens H, Halpern SL. An open-label, multicenter study of polyethylene glycol-L-asparaginase for the treatment of acute lymphoblastic leukemia. Cancer. 1995;75:1176-1181.
6. Muller HJ, Loning L, Horn A, et al. Pegylated asparaginase (Oncaspar) in children with ALL: drug monitoring in reinduction according to the ALL/NHL-BFM 95 protocols. Br J Haematol. 2000;110:379-384.
7. Jarrar M, Gaynon PS, Periclou AP, et al. Asparagine depletion after pegylated E. coli asparaginase treatment and induction outcome in children with acute lymphoblastic leukemia in first bone marrow relapse: A Children's Oncology Group study (CCG-1941). Pediatr Blood Cancer. 2006;47:141-146.
8. Rizzari C, Citterio M, Zucchetti M, et al. A pharmacological study on pegylated asparaginase used in front-line treatment of children with acute lymphoblastic leukemia. Haematologica. 2006;91:24-31.
9. Avramis VI, Sencer S, Periclou AP, et al. A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: a Children's Cancer Group study. Blood. 2002;99:1986-1994.
10. Rosen O, Muller HJ, Gokbuget N, et al. Pegylated asparaginase in combination with high-dose methotrexate for consolidation in adult acute lymphoblastic leukaemia in first remission: a pilot study. Br J Haematol. 2003;123:836-841.
11. Cheson BD, Cassileth PA, Head DR, et al. Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia. J Clin Oncol. 1990;8:813-819.
12. Larson RA, Dodge RK, Burns CP, et al. A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: cancer and leukemia group B study 8811. Blood. 1995;85:2025-2037.
13. Larson RA, Dodge RK, Linker CA, et al. A randomized controlled trial of filgrastim during remission induction and consolidation chemotherapy for adults with acute lymphoblastic leukemia: CALGB study 9111. Blood. 1998;92:1556-1564.
14. Fabry U, Korholz D, Jurgens H, Gobel U, Wahn V. Anaphylaxis to L-asparaginase during treatment for acute lymphoblastic leukemia in children - evidence of a complement-mediated mechanism. Pediatr Res. 1985;19:400-408.
15. Asselin BL, Lorenson MY, Whitin JC, et al. Measurement of serum L-asparagine in the presence of L-asparaginase requires the presence of an L-asparaginase inhibitor. Cancer Res. 1991;51:6568-6573.
16. Asselin BL. The three asparaginases. Comparative pharmacology and optimal use in childhood leukemia. Adv Exp Med Biol. 1999;457:621-629.
17. Cox DR. Regression models and life tables (with discussion). J Royal Stat Soc. 1972;74:187-226.
18. Wetzler M, Dodge RK, Mrozek K, et al. Prospective karyotype analysis in adult acute lymphoblastic leukemia: the cancer and leukemia Group B experience. Blood. 1999;93:3983-3993.
19. Judd CM, McClelland GH. Data Analysis: A Model Comparison Approach. San Diego, CA: Harcourt Brace Jovanovich; 1989.
20. Czuczman MS, Dodge RK, Stewart CC, et al. Value of immunophenotype in intensively treated adult acute lymphoblastic leukemia: cancer and leukemia Group B study 8364. Blood. 1999;93:3931-3939.